中文版 | English
Title

Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments

Author
Corresponding AuthorLu, Hongzhou
Publication Years
2022-08-01
DOI
Source Title
ISSN
1881-7831
EISSN
1881-784X
Volume16Issue:4
Abstract
The coronavirus disease 2019 (COVID-19) pandemic continues to ravage the world, and the virus' constant evolution has made it increasingly difficult to contain. The combination of the neutralizing antibodies amubarvimab and romlusevimab has recently been introduced as a treatment for COVID-19 in China. Based on its potential to effectively combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its Omicron variant at a modest cost and under medical insurance, this controversial biotherapy is anticipated to be widely available in China. Hopefully, whether and how the proposed medication will alter the treatment of COVID-19 in China will be apparent soon, as well as if it will help to reduce hospitalizations, reduce the incidence of severe illness, or even act as pre -exposure prophylaxis.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
First ; Corresponding
WOS Research Area
Pharmacology & Pharmacy
WOS Subject
Pharmacology & Pharmacy
WOS Accession No
WOS:000862826900008
Publisher
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:1
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/406514
DepartmentThe Third People's Hospital of Shenzhen
Affiliation
Southern Univ Sci & Technol, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis, 29 Bulan Rd, Shenzhen 518112, Guangdong, Peoples R China
First Author AffilicationThe Third People's Hospital of Shenzhen
Corresponding Author AffilicationThe Third People's Hospital of Shenzhen
First Author's First AffilicationThe Third People's Hospital of Shenzhen
Recommended Citation
GB/T 7714
Liu, Miaona,Li, Wei,Lu, Hongzhou. Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments[J]. Drug Discoveries and Therapeutics,2022,16(4).
APA
Liu, Miaona,Li, Wei,&Lu, Hongzhou.(2022).Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments.Drug Discoveries and Therapeutics,16(4).
MLA
Liu, Miaona,et al."Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments".Drug Discoveries and Therapeutics 16.4(2022).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Liu, Miaona]'s Articles
[Li, Wei]'s Articles
[Lu, Hongzhou]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Liu, Miaona]'s Articles
[Li, Wei]'s Articles
[Lu, Hongzhou]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liu, Miaona]'s Articles
[Li, Wei]'s Articles
[Lu, Hongzhou]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.